| Original language | English (US) |
|---|---|
| Article number | 1802093 |
| Journal | European Respiratory Journal |
| Volume | 53 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2019 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Respiratory Journal, Vol. 53, No. 3, 1802093, 01.03.2019.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis
T2 - A prospective pilot study
AU - Sgalla, Giacomo
AU - Larici, Anna Rita
AU - Sverzellati, Nicola
AU - Bartholmai, Brian
AU - Walsh, Simon L.F.
AU - Nikolic, Dragana
AU - Barney, Anna
AU - Fletcher, Sophie
AU - Jones, Mark
AU - Davies, Donna D.
AU - Richeldi, Luca
N1 - Funding Information: Support statement: The conduct of the study was supported by funding from the NIHR Southampton Respiratory Biomedical Research Unit (UK). Littmann 3200 electronic stethoscopes were provided by 3M through an educational grant. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Conflict of interest: G. Sgalla reports personal fees from Boehringer Ingelheim, outside the submitted work. A.R. Larici has nothing to disclose. N. Sverzellati reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. B. Bartholmai reports grants from NIH/NHLBI (he is Principal Investigator of the NHLBI Lung Tissue Research Consortium; Mayo Clinic receives funds for this project and B. Bartholmai’s effort), and personal fees from Promedior, LLC (for acting as a scientific advisor) and from Imbio, LLC (Mayo Clinic and B. Bartholmai receive fees/royalties from Imbio, LLC for the license of CALIPER analysis software), outside the submitted work. In addition, B. Bartholmai has a patent “systems and methods for analyzing in vivo tissue volumes using medical imaging” pending (which is relevant to the CALIPER functionality and visualisation of quantitative results). S.L.F. Walsh reports personal fees from Boehringer Ingelheim (speaker and consultancy fees), Roche (speaker and consultancy fees), Intermune (speaker fees), Bracco (speaker fees), and Sanofi-Genzyme (consultancy fees), outside the submitted work. D. Nikolic has nothing to disclose. A. Barney has nothing to disclose. S. Fletcher reports funding to attend conferences, speaker fees and fees for advisory boards from Roche and Boehringer Ingelheim. M. Jones has nothing to disclose. D.D. Davies reports she is a founder and shareholder of Synairgen and has received personal fees from Synairgen (consultant), outside the submitted work. L. Richeldi reports personal fees and other from Boehringer Ingelheim (trial principal investigator), grants and personal fees from InterMune, personal fees from Cipla and Vertex, and other from AstraZeneca, GlaxoSmithKline, Sanofi-Aventis, Celgene, Prometic, Roche and Takeda (scientific advisory boards), during the conduct of the study. Funding Information: The conduct of the study was supported by funding from the NIHR Southampton Respiratory Biomedical Research Unit (UK). Littmann 3200 electronic stethoscopes were provided by 3M through an educational grant. Funding information for this article has been deposited with the Crossref Funder Registry.
PY - 2019/3/1
Y1 - 2019/3/1
UR - http://www.scopus.com/inward/record.url?scp=85062623857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062623857&partnerID=8YFLogxK
U2 - 10.1183/13993003.02093-2018
DO - 10.1183/13993003.02093-2018
M3 - Letter
C2 - 30578384
AN - SCOPUS:85062623857
SN - 0903-1936
VL - 53
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 3
M1 - 1802093
ER -